Akihiko Okayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Akihiko Okayama has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Sherri Oliver Stuver
Boston University School of Public Health
5 shared publications - Masao Matsuoka
Kumamoto University
4 shared publications N Tachibana
4 shared publicationsHirohito Tsubouchi
Department of Internal Medicine II, Miyazaki Medical College, Miyazaki, Japan
3 shared publicationsN E Mueller
3 shared publicationsNancy Mueller
Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
3 shared publications
Latest Publications
- 1 June 2012
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 16, e338
Novel spotted fever group rickettsiosis? in a Japanese traveler returned from India
- 1 June 2012
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 16, e338
Novel spotted fever group rickettsiosis? in a Japanese traveler returned from India
- 1 January 2005
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 12 (1) , 46-50
The minimum number of clones necessary to sequence in order to obtain the maximum information about hepatitis C virus quasispecies: a comparison of subjects with and without liver cancer
Most studies of hepatitis C virus (HCV) quasispecies have reported the results of sequencing only three to five clones per sample. The possibility that sequencing so few clones might not provide a representative picture of the quasispecies present in a sample has never been evaluated. The present study was conducted to evaluate whether sequencing greater numbers of clones results in better information about the HCV quasispecies number and distribution, and to compare the HCV quasispecies in liver cancer cases and controls. RNA was extracted from serial serum samples from six subjects with HCV-associated liver cancer and 11 age- and sex-matched HCV-infected controls without liver cancer. The hypervariable region 1 (HVR1) of the HCV genome was amplified, cloned, and sequenced. For further studies of 12 serum samples from two liver cancer cases and two matched controls, successive groups of 10 additional clones were sequenced up to a total of 50 clones per serum sample. When only 10 clones were sequenced from each specimen, no consistent differences were seen between the number of HCV quasispecies in the six liver cancer cases and the 11 controls. However, sequencing 40 clones from each of 12 samples from two liver cancer cases and two controls revealed a greater number of quasispecies in liver cancer cases than in controls. Testing an additional 10 clones (50 clones per sample) did not significantly increase the number of quasispecies detected.
- 1 January 2005
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 12 (1) , 46-50
The minimum number of clones necessary to sequence in order to obtain the maximum information about hepatitis C virus quasispecies: a comparison of subjects with and without liver cancer
Most studies of hepatitis C virus (HCV) quasispecies have reported the results of sequencing only three to five clones per sample. The possibility that sequencing so few clones might not provide a representative picture of the quasispecies present in a sample has never been evaluated. The present study was conducted to evaluate whether sequencing greater numbers of clones results in better information about the HCV quasispecies number and distribution, and to compare the HCV quasispecies in liver cancer cases and controls. RNA was extracted from serial serum samples from six subjects with HCV-associated liver cancer and 11 age- and sex-matched HCV-infected controls without liver cancer. The hypervariable region 1 (HVR1) of the HCV genome was amplified, cloned, and sequenced. For further studies of 12 serum samples from two liver cancer cases and two matched controls, successive groups of 10 additional clones were sequenced up to a total of 50 clones per serum sample. When only 10 clones were sequenced from each specimen, no consistent differences were seen between the number of HCV quasispecies in the six liver cancer cases and the 11 controls. However, sequencing 40 clones from each of 12 samples from two liver cancer cases and two controls revealed a greater number of quasispecies in liver cancer cases than in controls. Testing an additional 10 clones (50 clones per sample) did not significantly increase the number of quasispecies detected.
- Open Access
- 15 March 2004
- Published by Wiley in International Journal of Cancer
- Vol. 110 (4) , 621-625
Role of HTLV‐1 proviral DNA load and clonality in the development of adult T‐cell leukemia/lymphoma in asymptomatic carriers
- 15 March 2004
- Published by Wiley in International Journal of Cancer
- Vol. 110 (4) , 621-625
Open AccessRole of HTLV‐1 proviral DNA load and clonality in the development of adult T‐cell leukemia/lymphoma in asymptomatic carriers
- Open Access
- 1 March 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 185 (5) , 691-695
Genetic Evidence of Transmission of Human T Cell Lymphotropic Virus Type 1 between Spouses
Sexual transmission of human T cell lymphotropic virus type 1 (HTLV-1) is considered to be an important route of infection in adults. However, no dir
- 1 March 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 185 (5) , 691-695
Open AccessGenetic Evidence of Transmission of Human T Cell Lymphotropic Virus Type 1 between Spouses
Sexual transmission of human T cell lymphotropic virus type 1 (HTLV-1) is considered to be an important route of infection in adults. However, no dir
- Open Access
- 1 April 2001
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 183 (7) , 1031-1037
Sequential Change of Virus Markers in Seroconverters with Community‐Acquired Infection of Human T Lymphotropic Virus Type I
Twenty-three human T lymphotropic virus type I (HTLV-I) seroconverters were identified among 1120 HTLV-I–seronegative adults followed up for 11 years in an area of Japan endemic for HTLV-I. The geometric mean titer of anti–HTLV-I was 1:453 in the first year after seroconversion; the titer of each subject did not change significantly during 2–10 years of follow-up. HTLV-I proviral DNA load was quantified in 15 seroconverters, and a broad range of levels was observed—from 1000 copies/105 peripheral blood mononuclear cells. However, there was no obvious change in HTLV-I proviral DNA load over several years within individual subjects. Therefore, both proviral DNA load and humoral response in adult HTLV-I seroconverters were shown to stabilize within a few years after initial infection. In addition, 1 subject tested positive for HTLV-I proviral DNA before antibody seroconversion, which suggests the existence of a window period in community-acquired infection
- 1 April 2001
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 183 (7) , 1031-1037
Open AccessSequential Change of Virus Markers in Seroconverters with Community‐Acquired Infection of Human T Lymphotropic Virus Type I
Twenty-three human T lymphotropic virus type I (HTLV-I) seroconverters were identified among 1120 HTLV-I–seronegative adults followed up for 11 years in an area of Japan endemic for HTLV-I. The geometric mean titer of anti–HTLV-I was 1:453 in the first year after seroconversion; the titer of each subject did not change significantly during 2–10 years of follow-up. HTLV-I proviral DNA load was quantified in 15 seroconverters, and a broad range of levels was observed—from 1000 copies/105 peripheral blood mononuclear cells. However, there was no obvious change in HTLV-I proviral DNA load over several years within individual subjects. Therefore, both proviral DNA load and humoral response in adult HTLV-I seroconverters were shown to stabilize within a few years after initial infection. In addition, 1 subject tested positive for HTLV-I proviral DNA before antibody seroconversion, which suggests the existence of a window period in community-acquired infection
- 22 September 2000
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 10 (3) , 165-168
Successful treatment using high-dose intravenous immunoglobulin in a patient with rapidly progressive interstitial pneumonia associated with dermatomyositis
A 36-year-old male patient with dermatomyo-sitis (DM) associated with rapidly progressive interstitial pneumonia (IP) was successfully treated by high-dose intravenous immunoglobulin (IVIG). He suffered from myopathy, skin lesions, and IP. In spite of the treatment with a high-dose corticosteroid, IP progressed rapidly. Then high-dose intravenous immunoglobulin (20 g/day, 4 days) was administered. The skin lesions, myopathy, and pulmonary lesions improved. High-dose IVIG was considered to be a relatively safe and effective treatment for progressive IP associated with DM.
- 22 September 2000
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 10 (3) , 165-168
Successful treatment using high-dose intravenous immunoglobulin in a patient with rapidly progressive interstitial pneumonia associated with dermatomyositis
A 36-year-old male patient with dermatomyo-sitis (DM) associated with rapidly progressive interstitial pneumonia (IP) was successfully treated by high-dose intravenous immunoglobulin (IVIG). He suffered from myopathy, skin lesions, and IP. In spite of the treatment with a high-dose corticosteroid, IP progressed rapidly. Then high-dose intravenous immunoglobulin (20 g/day, 4 days) was administered. The skin lesions, myopathy, and pulmonary lesions improved. High-dose IVIG was considered to be a relatively safe and effective treatment for progressive IP associated with DM.
- 1 June 2000
- Vol. 40 (3) , 627-32
[A case of mixed connective tissue disease with lupus-like manifestations of the central nervous system, successfully treated with cyclophosphamide combined with prednisolone].
A 29-year-old woman experienced Raynaud's phenomenon, swelling of her fingers, eruptions on her face, and muscle weakness in 1990. She was diagnosed as having mixed connective tissue disease (MCTD) and was treated with prednisolone (PSL) for 3 years. Most of her complaints disappeared after the treatment. In March 1997, she experienced fever, erythema, and lymphadenopathy. Although she was treated with PSL (20 mg/day) again, muscle weakness, mental disturbance, and recto-urinary disturbance appeared. When she was re-admitted to our hospital, increased levels of muscle-derived enzymes and positivity of anti-RNP antibody were found. High signal areas in her cerebrum were shown by magnetic resonance imaging, and slow and spike pattern was shown by electroencephalography. Hypoperfusion of the cerebral blood flow was suggested on single photon emission computed tomography. The number of mononuclear cells, amount of protein and level of interleukin-6 were found to be elevated in her cerebrospinal fluid (CSF). Her neurological manifestations were diagnosed as being due to MCTD, and showed characteristics similar to those of systemic lupus erythematosus. She was treated with PSL (60 mg/day) followed by steroid pulse therapy. Because the response to this treatment was partial, oral administration of cyclophosphamide (CPM) (100 mg/day) was added. Muscle weakness and neurological abnormalities as well as abnormal laboratory findings gradually improved over the following two months. We conclude that the treatment with CPM combined with PSL may be useful, when neurological manifestations of MCTD are serious and resistant to conventional therapy.
- 1 June 2000
- Vol. 40 (3) , 627-32
[A case of mixed connective tissue disease with lupus-like manifestations of the central nervous system, successfully treated with cyclophosphamide combined with prednisolone].
A 29-year-old woman experienced Raynaud's phenomenon, swelling of her fingers, eruptions on her face, and muscle weakness in 1990. She was diagnosed as having mixed connective tissue disease (MCTD) and was treated with prednisolone (PSL) for 3 years. Most of her complaints disappeared after the treatment. In March 1997, she experienced fever, erythema, and lymphadenopathy. Although she was treated with PSL (20 mg/day) again, muscle weakness, mental disturbance, and recto-urinary disturbance appeared. When she was re-admitted to our hospital, increased levels of muscle-derived enzymes and positivity of anti-RNP antibody were found. High signal areas in her cerebrum were shown by magnetic resonance imaging, and slow and spike pattern was shown by electroencephalography. Hypoperfusion of the cerebral blood flow was suggested on single photon emission computed tomography. The number of mononuclear cells, amount of protein and level of interleukin-6 were found to be elevated in her cerebrospinal fluid (CSF). Her neurological manifestations were diagnosed as being due to MCTD, and showed characteristics similar to those of systemic lupus erythematosus. She was treated with PSL (60 mg/day) followed by steroid pulse therapy. Because the response to this treatment was partial, oral administration of cyclophosphamide (CPM) (100 mg/day) was added. Muscle weakness and neurological abnormalities as well as abnormal laboratory findings gradually improved over the following two months. We conclude that the treatment with CPM combined with PSL may be useful, when neurological manifestations of MCTD are serious and resistant to conventional therapy.
- 1 August 1999
- Published by Wiley in Transfusion
- Vol. 39 (8) , 795-800
Can blood transfusion transmit disease‐producing genes?
- 1 August 1999
- Published by Wiley in Transfusion
- Vol. 39 (8) , 795-800
Can blood transfusion transmit disease‐producing genes?
- 1 April 1999
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 20 (4) , A51
GENDER DIFFERENCE IN PREVALENCE OF PPD ANERGY AMONG HUMAN T-LYMPHOTROPIC VIRUS TYPE I CARRIERS IN JAPAN
- 1 April 1999
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 20 (4) , A51
GENDER DIFFERENCE IN PREVALENCE OF PPD ANERGY AMONG HUMAN T-LYMPHOTROPIC VIRUS TYPE I CARRIERS IN JAPAN